Stockscreener 앱 받기
57.33
3.58%
-2.13
시간 외 거래:
57.33
전일 마감가:
$59.46
열려 있는:
$59.31
하루 거래량:
3.52M
Relative Volume:
1.55
시가총액:
$10.99B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
21.31
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-1.39%
1개월 성능:
-1.14%
6개월 성능:
-10.32%
1년 성능:
-34.78%
1일 변동 폭
$56.36
$60.09
1주일 범위
$56.36
$63.97
52주 변동 폭
$52.93
$94.85
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
57.33 | 11.65B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - inkl
BioMarin stock rating reiterated at Buy by Stifel on strong Q2 results - Investing.com
BMRN Makes Bullish Cross Above Critical Moving Average - Nasdaq
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating - MarketScreener
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View - Yahoo Finance
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin: Q2 Earnings Snapshot - New Haven Register
BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin’s Earnings Beat Forecasts And Hike Guidance For 2025 - Finimize
BioMarin Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
BioMarin (BMRN) Q2 Revenue Jumps 16% - The Motley Fool
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises - Investing.com
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioMarin Pharmaceutical Reports Strong Q2 EarningsNews and Statistics - IndexBox
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars - TradingView
BioMarin Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q2 Revenue $825.0M, vs. FactSet Est of $761.7M - MarketScreener
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS - PR Newswire
What makes BioMarin Pharmaceutical Inc. stock price move sharplyGet real-time alerts on top-performing stocks - Jammu Links News
How does BioMarin Pharmaceutical Inc. compare to its industry peersBuild a portfolio that grows with the market - Jammu Links News
Is BioMarin Pharmaceutical Inc. a good long term investmentCapitalize on emerging industry trends - Jammu Links News
How volatile is BioMarin Pharmaceutical Inc. stock compared to the marketHigh-octane gains - Jammu Links News
What is the dividend policy of BioMarin Pharmaceutical Inc. stockSuperior trading gains - Jammu Links News
BioMarin Pharmaceuticals Appoints Ian T. Clark to Board of Directors - AInvest
When is BioMarin Pharmaceutical Inc. stock expected to show significant growthBuild capital through low-risk investments - Jammu Links News
What is BioMarin Pharmaceutical Inc. company’s growth strategySky-high profits - Jammu Links News
Is it the right time to buy BioMarin Pharmaceutical Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are analysts’ price targets for BioMarin Pharmaceutical Inc. in the next 12 monthsSuperior investment outcomes - Jammu Links News
Published on: 2025-08-03 23:11:15 - Jammu Links News
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher in 2025Unlock powerful stock screening for profits - Jammu Links News
What are the technical indicators suggesting about BioMarin Pharmaceutical Inc.Free Bull & Bear Market Updates - Jammu Links News
How strong is BioMarin Pharmaceutical Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
Is BioMarin Pharmaceutical Inc. a growth stock or a value stockMaximize returns with smart investment plans - Jammu Links News
What are BioMarin Pharmaceutical Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
BioMarin Expands Board with New Director Appointment - MSN
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):